Kay Emm Biomedicals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-10-2024
- Paid Up Capital ₹ 1.00 M
as on 23-10-2024
- Company Age 23 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.25 Cr
as on 23-10-2024
- Satisfied Charges ₹ 1.87 Cr
as on 23-10-2024
- Revenue %
(FY 2023)
- Ebitda
- Net Worth
- Total Assets %
(FY 2023)
About Kay Emm Biomedicals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹3.25 Cr. The company has closed loans amounting to ₹1.87 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Aggarwal, Dimple Aggarwal, and Rakhi Aggarwal serve as directors at the Company.
- CIN/LLPIN
U24232CH2001PTC024631
- Company No.
024631
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Sep 2001
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- LocationU T, Chandigarh
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kay Emm Biomedicals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Aggarwal  | Director | 10-Sep-2001 | Current |
| Dimple Aggarwal | Director | 10-Sep-2001 | Current |
| Rakhi Aggarwal | Director | 10-Sep-2001 | Current |
Financial Performance and Corporate Structure Insights of Kay Emm Biomedicals.
Kay Emm Biomedicals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Kay Emm Biomedicals?
In 2023, Kay Emm Biomedicals had a promoter holding of 99.00% and a public holding of 1.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 25 Jun 2012 | ₹2.15 Cr | Open |
Centurian Bank Of Punjab Limited Creation Date: 22 Mar 2004 | ₹7.50 M | Open |
Bankofpunjabltd. Creation Date: 22 Mar 2004 | ₹2.50 M | Open |
How Many Employees Work at Kay Emm Biomedicals?
Unlock and access historical data on people associated with Kay Emm Biomedicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kay Emm Biomedicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kay Emm Biomedicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
